Our study confirms that in U87 and U373 GBM cells treated with the standard dose of bevacizumab, which mimics clinical administration, the migration of brain endothelial cells decreases in vitro and in vivo, with no effect observed in VEGF/VEGFR2 signaling. The gene discussed is KDR; the disease is glioblastoma.